Janssen, a brand name that for six decades has been emblazoned on Johnson & Johnson’s pharmaceutical laboratories and prescription drugs, will be phased out as part of a corporate rebranding in the wake of the healthcare giant splitting in two.

詹森（Janssen）是一个在强生制药实验室和处方药方面已经发展了六十年的品牌，在医疗保健大分为二之后，将作为公司更名的一部分逐步淘汰。

Taking its place will be a new name, Johnson & Johnson Innovative Medicine, which the company says better reflects the research and development work the division does. The change was made alongside a redesign of J&J’s classic cursive script into a more modern sans-serif typeface. The company’s medical device business, which J&J retained after spinning off its consumer health arm, will remain Johnson & Johnson MedTech..

取而代之的将是强生创新医学的新名称，公司表示更好地反映了该部门的研发工作。这一变化是在J＆J经典咒语脚本重新设计成更现代的无衬线字体的同时进行的。该公司的医疗器械业务，J＆J在脱离其消费者健康部门后保留下来，将继续保持强生医疗技术。。

“Our updated brand identity communicates our bold approach to innovation in healthcare while staying true to the care we share to patients, doctors, nurses and those who use our products,” Tesia Williams, a senior director of corporate media relations at J&J, wrote in an email.

J＆J公司媒体关系高级总监Tesia Williams写道：“我们更新的品牌身份传达了我们大胆的医疗保健创新方法，同时坚持我们与患者，医生，护士和使用我们产品的人分享的护理，写在一封电子邮件中。

Janssen was named for Paul Janssen, a Belgian scientist and doctor who in 1953 started a research laboratory in a small town outside of Antwerp. Nearly a decade later, J&J bought the company, then called Janssen Pharmaceutica, and folded it into its expanding pharmaceutical empire.

詹森以比利时科学家兼医生保罗·詹森（Paul Janssen）的名字命名，他于1953年在安特卫普以外的一个小镇上建立了一个研究实验室。近十年后，J＆J收购了该公司，然后称之为Janssen Pharmaceutica，并将其折叠成不断扩大的制药帝国。

The division became the corporate home for a number of J&J’s subsequent acquisitions, including of Centocor, Crucell, Ortho Biotech and, most recently, Actelion. It’s produced many of J&J’s top-selling medicines, among them Risperdal, Remicade, Simponi and Zytiga.

该部门成为J＆J随后收购的公司所在地，包括Centocor，Crucell，Ortho Biotech以及最近的Actelion。它生产了许多J＆J最畅销的药物，其中包括Risperdal，Remicade，Simponi和Zytiga。

The Janssen brand is seen on boxes of the company’s COVID-19 vaccine.

Janssen品牌可在公司的COVID-19疫苗盒上看到。

Jon Cherry via Getty Images

Jon Cherry通过Getty的形象

“We understand there is significant equity in the Janssen name, and we are committed to bringing stakeholders along on the journey as we step into our future as a unified Johnson & Johnson brand,” wrote Williams, who added that the transition will take time.

威廉姆斯补充说：“我们了解詹森的名字有很大的股权，我们致力于将利益相关者带到旅程中，因为我们作为一个统一的强生品牌走向未来。”他补充说，转型将需要时间。

It’s a journey that a number of J&J’s large pharmaceutical peers have taken in recent years. Back in 2019, AstraZeneca retired the MedImmune brand it used for years to house some of its drug R&D after acquiring the biotechnology company of the same name in 2007. More recently, in 2022, Sanofi phased out the Genzyme name for its specialty medicine unit, consigning that storied branding to the biotech history books..

这是J＆J近年来大型制药同行的旅程。早在2019年，阿斯利康（AstraZeneca）在2007年收购同名生物技术公司后，退休了多年来用于容纳部分药物研发的MedImmune品牌。最近，在2022年，赛诺菲逐步淘汰其特种医学部门的Genzyme名称，将该品牌委托给生物技术历史书籍。。

Other biotech names synonymous with the industry’s coming-of-age in the 1980s, like Immunex, Shire and Celgene, have faded following their acquisitions by bigger pharma companies. One exception: Genentech, the industry’s original standard bearer, still operates as a distinct subsidiary under Roche.

其他生物技术名称与20世纪80年代的行业成熟同义，如Immunex，Shire和Celgene，在大型制药公司收购后已经褪色。一个例外是：Genentech是该行业的原始标准持有者，仍然是罗氏的独立子公司。